热门资讯> 正文
Phathom Pharma announces Voquezna label expansion
2024-07-18 23:09
- Phathom Pharmaceuticals(PHAT) 0
- 阿利科(ALCO) 0
- LISTED FUND TRUST ROUNDHILL BITKRAFT ESPORTS & DIG ENT ETF(NERD) 0
- Phathom Pharmaceuticals (NASDAQ:PHAT) announced Thursday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its lead product, vonoprazan, allowing its use for a medical condition characterized by heartburn.
- The latest approval allows vonoprazan’s use for adults with heartburn associated with non-erosive gastroesophageal reflux disease (GERD).
- Non-erosive GERD represents the largest category of GERD, a gastrointestinal condition characterized by a burning sensation in the chest due to stomach acid flowing back into the esophagus.
- The company said that the approval was backed by its PHALCON-NERD-301 study, which reached the primary endpoint, indicating a quick and significant reduction of heartburn with daily vonoprazan treatment.
- The FDA has previously approved Vonoprazan, branded Voquezna, for erosive GERD and as a combination therapy with antibiotics for Helicobacter pylori (H. pylori) infection.
More on Phathom Pharmaceuticals
- Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays
- Phathom Pharmaceuticals, Inc. (PHAT) Q1 2024 Earnings Call Transcript
- Phathom Pharmaceuticals Non-GAAP EPS of -$1.11 beats by $0.06, revenue of $1.91M misses by $0.23M
- Phathom a buy at Stifel on new heartburn therapy
- Seeking Alpha’s Quant Rating on Phathom Pharmaceuticals
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
